Martin Shkreli, the former hedge fund manager known as “Pharma Bro,” defended Palantir Technologies Inc.’s valuation on Tuesday amid the company’s surging stock price, projecting substantial cash flow growth for the data analytics firm through 2025.
‘Pharma Bro’ Martin Shkreli Defends Palantir’s Valuation Amid 24% Surge, Says AI Firm’s Cash Flow Justifies ‘Expensive’ Price
